^
Association details:
| Biomarker: | EGFR exon 19 deletion |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Rybrevant (amivantamab-vmjw) (EGFR inhibitor, c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
Published date:
09/19/2024
Excerpt:
Johnson & Johnson...the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) in combination with standard of care chemotherapy (carboplatin and pemetrexed) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor (TKI).
Source:
Published date:
12/21/2023
Excerpt:
Non-Small Cell Lung Cancer: EGFR Exon 19 Deletion or Exon 21 L858R…Subsequent therapy...Amivantamab-vmjw + carboplatin + pemetrexed (nonsquamous)...
Secondary therapy:
carboplatin + pemetrexed
